Insider Trading Alert - UNP, OPK And NVAX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 21, 2014, 95 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $237.64 to $58,561,295.00.

Highlighted Stocks Traded by Insiders:

Union Pacific (UNP) - FREE Research Report

Totusek Jeffrey P who is Vp Controller & Cao Upc at Union Pacific sold 8,340 shares at $187.58 on March 21, 2014. Following this transaction, the Vp Controller & Cao Upc owned 86,581 shares meaning that the stake was reduced by 8.79% with the 8,340-share transaction.

The shares most recently traded at $187.33, down $0.25, or 0.13% since the insider transaction. Historical insider transactions for Union Pacific go as follows:

  • 4-Week # shares sold: 25,959
  • 12-Week # shares sold: 28,153
  • 24-Week # shares sold: 43,539

The average volume for Union Pacific has been 2.0 million shares per day over the past 30 days. Union Pacific has a market cap of $85.0 billion and is part of the services sector and transportation industry. Shares are up 11.22% year-to-date as of the close of trading on Thursday.

Union Pacific Corporation, through its subsidiary, Union Pacific Railroad Company, provides rail transportation services in the United States. The stock currently has a dividend yield of 1.92%. The company has a P/E ratio of 20.1. Currently there are 16 analysts that rate Union Pacific a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UNP - FREE

TheStreet Quant Ratings rates Union Pacific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Union Pacific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 34,600 shares at $9.74 on March 21, 2014. Following this transaction, the CEO & Chairman owned 139.6 million shares meaning that the stake was reduced by 0.02% with the 34,600-share transaction.

The shares most recently traded at $9.35, down $0.39, or 4.16% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.1 million shares per day over the past 30 days. Opko Health has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 14.46% year-to-date as of the close of trading on Thursday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Novavax (NVAX) - FREE Research Report

Cadila Pharmaceuticals Ltd who is 10% Owner at Novavax sold 3.0 million shares at $4.95 on March 21, 2014. Following this transaction, the 10% Owner owned 9.5 million shares meaning that the stake was reduced by 24% with the 3.0 million-share transaction.

Modi Rajiv I. who is Director at Novavax sold 3.0 million shares at $4.95 on March 21, 2014. Following this transaction, the Director owned 9.5 million shares meaning that the stake was reduced by 24% with the 3.0 million-share transaction.

The shares most recently traded at $4.68, down $0.27, or 5.77% since the insider transaction. Historical insider transactions for Novavax go as follows:

  • 4-Week # shares bought: 40,154
  • 12-Week # shares bought: 40,154
  • 24-Week # shares bought: 40,154

The average volume for Novavax has been 4.9 million shares per day over the past 30 days. Novavax has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are down 3.12% year-to-date as of the close of trading on Thursday.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. Currently there are 4 analysts that rate Novavax a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NVAX - FREE

TheStreet Quant Ratings rates Novavax as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Novavax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss